Table 49.
Country | N | GEN | CHL | AMP | CTX | CAZ | MEM | TGC |
---|---|---|---|---|---|---|---|---|
Germany | 171 | 12.9 | 16.4 | 64.3 | 5.3 | 5.3 | 0 | 0 |
Italy | 170 | 10.6 | 19.4 | 76.5 | 0.6 | 1.2 | 0 | 0 |
Netherlands | 132 | 9.1 | 24.2 | 74.2 | 1.5 | 6.1 | 0 | 0 |
Total (3 MSs) | 473 | 11 | 19.7 | 71.5 | 2.5 | 4 | 0 | 0 |
Country | N | NAL | CIP | AZM | COL | SMX | TMP | TET |
---|---|---|---|---|---|---|---|---|
Germany | 171 | 27.5 | 38 | 5.8 | 9.9 | 44.4 | 31.6 | 57.3 |
Italy | 170 | 43.5 | 55.9 | 5.9 | 11.8 | 60.6 | 60 | 65.9 |
Netherlands | 132 | 28 | 42.4 | 4.5 | 8.3 | 46.2 | 28 | 55.3 |
Total (3 MSs) | 473 | 33.4 | 45.7 | 5.5 | 10.1 | 50.7 | 40.8 | 59.8 |
ECOFFs: epidemiological cut‐off values; MSs: Member States; N: number of isolates tested; GEN: gentamicin; CHL: chloramphenicol; AMP: ampicillin; CTX: cefotaxime; CAZ: Ceftazidime; MEM: meropenem; TGC: tigecycline; NAL: nalidixic acid; CIP: ciprofloxacin; AZM: azithromycin; COL: colistin; SMX: sulfamethoxazole; TMP: trimethoprim; TET: tetracycline.